RealClearPolicy: Can We Please Get Serious About Patents and Drug Pricing? By Bernard Cassidy
In a recent letter to the U.S. Patent and Trademark Office (USPTO), eleven Members of Congress sounded an electrifying alarm, stating that the USPTO has been “frequently” denying petitions for inter partes review (IPR), which “has made… Read More »